Tremendous progress has been achieved in multiple myeloma management in the past 25 years with the approval of IMiDs, PIs, and anti-CD38 mAbs, resulting in a major paradigm shift in myeloma treatment (Figure 1). Here, CD38 is linked to plasma cell myeloma.